Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine (GB:0K6R)
LSE:0K6R
Neurocrine (0K6R) Share Price & Analysis
0 Followers
0K6R Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$89.66 - $148.34
Previous Close$139.53
Volume310.00
Average Volume (3M)943.00
Market Cap
$13.94B
Enterprise Value$13.34B
Total Cash (Recent Filing)$1.03B
Total Debt (Recent Filing)$428.40M
Price to Earnings (P/E)N/A
Beta0.86
Next Earnings
May 01, 2024EPS Estimate
$1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding99,507,490
10 Day Avg. Volume17
30 Day Avg. Volume943
Standard Deviation0.13
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)6.06
Price to Sales (P/S)21.22
Price to Cash Flow (P/CF)26.90
P/FCF Ratio28.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.07
Enterprise Value/Gross Profit7.22
Enterprise Value/Ebitda39.18
Forecast
1Y Price Target
$153.90Price Target Upside10.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
Neurocrine News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsNeurocrine Biosciences reported positive topline data from the phase 2 SAVITRI study in adults with major depressive disorder, meeting primary and secondary endpoints and demonstrating competitive efficacy.
Drug DevelopmentCrinecerfont could be a $1.5B peak drug and is still underappreciated, with potential blockbuster 3rd and 4th acts in the company's pipeline, indicating significant growth potential.
Market AdvantageWith the failure of competitor drug tildacerfont to show a benefit in adult CAH patients, Neurocrine Biosciences' crinecerfont is likely to have a first-mover advantage, boosting its market potential.
Bears Say
Clinical Trial FailuresTildacerfont's late-stage study results in congenital adrenal hyperplasia were disappointing, failing to meet the primary endpoint.
Drug Development SetbacksNovartis discontinued development due to safety/tolerability concerns, particularly with amnesia, dissociation, and sedation.
Financial PerformanceHigher-than-expected OpEx guidance could weigh on EPS this year.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.77% Other Institutional Investors
98.23% Public Companies and
Individual Investors
0K6R FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest share price was $89.66 and its highest was $148.34 in the past 12 months.
What is Neurocrine’s market cap?
Currently, no data Available
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is May 01, 2024 which is in 6 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Feb 07, 2024. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.212 by $0.228.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is $1.1.
How many shares outstanding does Neurocrine have?
Currently, no data Available
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.44 in its last earnings report, beating expectations of $1.212. Following the earnings report the stock price went down -2.465%.
Which hedge fund is a major shareholder of Neurocrine?
Among the largest hedge funds holding Neurocrine’s share is Dodge & Cox. It holds Neurocrine’s shares valued at 166M.
---
Neurocrine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$153.90 (10.30% Upside)
$153.90 (10.30% Upside)
Blogger Sentiment
Bullish
GB:0K6R Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.48%
12-Months-Change
Fundamentals
Return on Equity
12.68%
Trailing 12-Months
Asset Growth
38.66%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
0K6R Company Deck
---
0K6R Earnings Call
Q4 2024
0:00 / 0:00
---
0K6R Stock 12 Months Forecast
Average Price Target
$153.90
▲(10.30% Upside)
Technical Analysis
Best Analysts Covering 0K6R
1 Year
1 Year Success Rate
16/18 ratings generated profit
1 Year Average Return
+17.10%
reiterated a buy rating 2 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +17.10% per trade.
---